logo
Avgolemono: It's all Greek for National Soup Month

Avgolemono: It's all Greek for National Soup Month

Yahoo29-01-2025

When Ioannis Bougiouris was a boy in Athens, he split his time between the city he called home and the village where his mother grew up, Vresthena.
'For the holidays, for the weekends and every summer, we used to go,' says Bougiouris, chef/owner of Zorba's Kitchen in Orlando.
There, his grandmother, Olga, lived among the villagers, 'maybe 200 people,' he says (a recent Greek census puts the number at 333).
'She was the one who taught my mom to cook. And she was always cooking for everybody, all the kids, all the grandkids.'
And among the things he has remembered for so long that he cannot remember when he started remembering them was avgolemono.
'It is like medicine!' he says. 'When somebody was getting sick, you wouldn't hear anybody say, 'I need a doctor. My grandmother would say, 'I got you. I make you the avgolemono soup.''
Zorba's Kitchen is mini, but mighty in its Med-based fare | Review
At its foundation, not surprisingly, avgolemono is what every other culture in the world employs during flu season: chicken broth.
But this steaming cauldron of penicillin has its own unique twist that the name gives away up front, eggs and lemon, the former of which imparts a silky, creamy texture, the latter a wonderful burst of tartness.
In Greece, and perhaps even more so in the States, avgolemono is considered a staple, something you'll find on virtually all Greek menus or at least, as is the case at Zorba's, a regularly rotating special, but many people — including those I spoke to for this piece — are unaware that its roots, which date back as far as the 10th Century, lie in Spain, and its Sephardic Jewish community.
I didn't know, either. But the quest for knowledge took me down a warm and wonderful rabbit hole for this, the last in our National Soup Month series for 2025 (and on a day that began with 40 degree temps, yikes!).
Born of a dressing called agristada, which combined lemon with egg to make a creamy, zesty accompaniment that adhered to kosher dietary laws, the Jewish people took with it them when they were expelled from Spain during the Inquisition, wrote Nosher's Emily Paster, and introduced it to the Mediterranean cultures where they settled, including Turkey, Italy and Greece.
'Ottoman diners already had a penchant for sour flavors…' Paster wrote. 'So it is not surprising that agristada, with its lemony bite, became part of the larger Greek and Turkish cuisine.'
Over time, agristada morphed into a variety of dishes and condiments still used today in these countries, avgolemono perhaps the most famous of all.
'It is so unique and most important, it's so healthy,' says Vassilis Coumbaros, chef/owner of festive I-Drive favorite Taverna Opa, where every day you'll find the same version of the soup the Coumbaros family eats at home.
Like Bougiouris, his personal history with the soup begins with his yia yia.
'She always would boil the chickens, make some rice … and the egg you put in just to thicken it up.'
Timing and temperature, says Coumbaros, are the secret ingredients.
'After the beginning — you make the mirepoix (carrots, onions, celery) — and you put it in the hot water with the chicken and let it boil for about an hour. Then, when you take the ingredients out, in order to succeed, you have to drop the temperature of the broth down to about 90 degrees.'
At the restaurant, a thermometer is employed. At home, a finger.
'Like my grandma used to do it,' he says. 'She'd say if her finger could tolerate the temperature, then it's good to mix.'
This is because soup that's too hot will cook the eggs rather than temper them.
Some chefs, and both chefs' grandmothers, would beat yolks and white separately before combining them with a few ladles full of cooler broth. Leaving the eggs out of the fridge for a spell helps, too, bringing them a little closer to room temperature. Steady stirring helps blend the eggs and broth together before a similar, slow and steady technique allows for combining with the larger pot of cooled-off soup.
Lemon is at the chefs' discretion.
'I make it quite lemony here at the restaurant, which is how the people like it,' says Bougiouris, whose version skips the mirepoix. Fall-apart soup chicken and rice are added later, though, in later years, some regions of Greece began using orzo instead.
'In the restaurant, I like to add some dill and a little green onions for extra flavor,' says Coumbaros, chuckling.
Meaty Beany Chili is a one-pot, plant-based super stew
Green is always an appetizing touch on any plate (he doesn't do it at home; the kids don't like it), but grandma's recipe is something everyone loves when the weather gets cold, he says. Or if you happen to catch one.
'If we were sick or had a light flu or fever, she would always give us chicken-lemon soup,' he says. 'It's free medicine!'
Open up and say ahhhhh.
Find me on Facebook, X or Instagram (@amydroo) or on the OSFoodie Instagram account @orlando.foodie. Email: amthompson@orlandosentinel.com. For more fun, join the Let's Eat, Orlando Facebook group.
Taverna Opa Orlando: 9101 International Drive in Orlando, 407-351-8660; opaorlando.com
Zorba's Kitchen: 7325 Lake Underhill Road in Orlando, 407-270-6505; instagram.com/zorbas_orlando

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China

Yahoo

time41 minutes ago

  • Yahoo

NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China

LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit hyperactivity disorder (ADHD), today announced a notice of allowance in China for a patent protecting the Monarch eTNS System. The patent, titled Pulse Generator for Trigeminal Nerve Stimulation, protects certain embodiments of NeuroSigma's core eTNS technology, including its second-generation Monarch device. The patent was allowed by China's National Intellectual Property Administration on May 27, 2025. In 2022, NeuroSigma licensed rights to the Monarch eTNS System for treating ADHD in China to Ignis Therapeutics, a leader in the development of novel therapeutics for central nervous system (CNS) conditions. 'As NeuroSigma continues to grow and work with our partners at Ignis, China will be a critical market for the Monarch eTNS System,' said Colin Kealey, M.D., President and CEO of NeuroSigma. 'This patent protects our second-generation Monarch device in China and significantly strengthens the company's intellectual property position.' "NeuroSigma's Monarch eTNS System is a highly innovative and effective therapy for ADHD,' added Tom Paschall, Director of NeuroSigma and CEO of Checkmate Capital. 'China is one of the largest and most important markets in the world for new CNS therapies. With this patent award, the Monarch device will benefit from robust intellectual property protection, which, we believe, will facilitate commercialization in this key market.' About NeuroSigma NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit For more information on the Monarch eTNS System, please visit Contact:Colin Kealey, M.D., President of NeuroSigma at CKealey@

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025

Business Wire

timean hour ago

  • Business Wire

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit

Phillips Medisize introduces medical connectors to enhance device integration
Phillips Medisize introduces medical connectors to enhance device integration

Yahoo

timean hour ago

  • Yahoo

Phillips Medisize introduces medical connectors to enhance device integration

Molex company Phillips Medisize has introduced TheraVolt Medical Connectors to enhance integration, performance and functionality of the devices, addressing the needs of medical device engineers. The launch marks the company's entry into the medical connector market under its own brand. These connectors aim to meet the increasing demand, spurred by the quick adoption of pulsed field ablation (PFA) technology. They are said to offer improved functionality, handling both signals and high-voltage lines. TheraVolt Medical Connectors claim to have cross-platform compatibility, which simplifies device integration, extends the life of capital equipment, and minimises both customisation development time and expenses. This is particularly beneficial for the companies that develop PFA treatments for individuals with atrial fibrillation. The connectors offer several key features, including high pin count and voltage clearance, which facilitate the integration of additional functionalities into multi-therapy medical devices. They also provide flexibility of the design and customisation, with off-the-shelf availability and options for tailoring to specific application demands. Sterilisation compatibility is another key feature, as TheraVolt Medical Connectors are designed to withstand several autoclave cycles without compromising integrity and performance. Additionally, they are designed for safety and reliability, supporting compliance with IEC and IPC needs for dependable operation in medical applications. Phillips Medisize has announced that further medical connectors are currently being developed and are expected to be released in the next 18 to 24 months. Phillips Medisize medtech segment vice-president Pete Soupir said: 'With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers.' In 2023, Phillips Medisize partnered with GlucoModicum, a Finland-based medtech company, to work on a non-invasive, needle-free continuous glucose monitor. "Phillips Medisize introduces medical connectors to enhance device integration" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store